Gabapentin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gabapentin" in English language version.

Last modified: 05:56:02, 16 August 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

252154nih.gov

5^th place

180111doi.org

2^nd place

7841semanticscholar.org

15^th place

8^th place

3222web.archive.org

1^st place

108books.google.com

3^rd place

51medscape.com

1,078^th place

916^th place

43drugs.com

529^th place

550^th place

43reuters.com

38^th place

30^th place

43wsj.com

94^th place

66^th place

41cbsnews.com

136^th place

93^rd place

33adsabs.harvard.edu

14^th place

9^th place

32patents.google.com

1,154^th place

606^th place

31nice.org.uk

4,081^st place

3,905^th place

31nihr.ac.uk

low place

7,409^th place

31plumbsveterinarydrugs.com

low place

22clincalc.com

5,833^rd place

4,432^nd place

22springer.com

182^nd place

172^nd place

22gov.uk

401^st place

228^th place

21hdl.handle.net

66^th place

34^th place

21nytimes.com

7^th place

21fda.gov

470^th place

329^th place

21amcp.org

low place

21businessweek.com

945^th place

628^th place

21healthcarelawinsights.com

low place

21akc.org

2,789^th place

2,304^th place

11tga.gov.au

4,353^rd place

2,806^th place

11in.gov.br

3,835^th place

6,615^th place

11fass.se

low place

11osf.io

8,809^th place

5,705^th place

11ucl.ac.uk

1,187^th place

756^th place

11helmholtz-muenchen.de

low place

11ox.ac.uk

541^st place

356^th place

11nhs.uk

2,637^th place

2,254^th place

11psychiatria-danubina.com

low place

11mayoclinic.org

2,191^st place

1,798^th place

11medicalnewstoday.com

3,865^th place

3,829^th place

11sciencedirect.com

137^th place

146^th place

11worldcat.org

4^th place

11bmj.com

1,341^st place

1,425^th place

11goodrx.com

low place

11nursingnotes.co.uk

low place

11publishing.service.gov.uk

1,837^th place

948^th place

11usdoj.gov

4,271^st place

2,616^th place

11ky.gov

2,697^th place

1,238^th place

11wvlegislature.gov

low place

7,613^th place

11tn.gov

4,493^rd place

2,108^th place

11alabamapublichealth.gov

low place

11utah.gov

2,710^th place

1,330^th place

11virginia.gov

1,338^th place

592^nd place

11sfgate.com

248^th place

142^nd place

11bloomberg.com

118^th place

85^th place

11scotusblog.com

6,074^th place

2,913^th place

11drugfree.org

low place

11ktla.com

5,255^th place

2,760^th place

11justice.gov

884^th place

477^th place

11nbcnews.com

156^th place

101^st place

11washingtonmonthly.com

6,261^st place

3,625^th place

11dallasnews.com

903^rd place

457^th place

11thestreet.com

5,850^th place

3,428^th place

11rug.nl

2,629^th place

1,971^st place

11businesswire.com

828^th place

485^th place

11pfizer.com

low place

11viatris.com

low place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS (December 2010). "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials". PLOS ONE. 5 (12) e14433. Bibcode:2010PLoSO...514433P. doi:10.1371/journal.pone.0014433. PMC 3010990. PMID 21203440.
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM (October 1999). "Selective expression of the large neutral amino acid transporter at the blood-brain barrier". Proceedings of the National Academy of Sciences of the United States of America. 96 (21): 12079–12084. Bibcode:1999PNAS...9612079B. doi:10.1073/pnas.96.21.12079. PMC 18415. PMID 10518579.
Chan AY, Yuen AS, Tsai DH, Lau WC, Jani YH, Hsia Y, et al. (August 2023). "Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study" (PDF). Nature Communications. 14 (1) 5005. Bibcode:2023NatCo..14.5005C. doi:10.1038/s41467-023-40637-8. PMC 10435503. PMID 37591833.

akc.org (Global: 2,789^th place; English: 2,304^th place)

Coile C (31 October 2022). "Gabapentin for Dogs: Uses and Side Effects". American Kennel Club. Archived from the original on 6 December 2022. Retrieved 12 May 2023.

alabamapublichealth.gov (Global: low place; English: low place)

"Pharmacy Division". Alabama Department of Public Health (ADPH). Retrieved 30 May 2020.

amcp.org (Global: low place; English: low place)

Mack A (2003). "Examination of the evidence for off-label use of gabapentin" (PDF). Journal of Managed Care Pharmacy. 9 (6): 559–568. doi:10.18553/jmcp.2003.9.6.559. PMC 10437292. PMID 14664664. Archived from the original (PDF) on 17 September 2010. Retrieved 15 August 2006.

bloomberg.com (Global: 118^th place; English: 85^th place)

Van Voris B, Lawrence J (26 March 2010). "Pfizer Told to Pay $142.1 Million for Neurontin Marketing Fraud". Bloomberg News. Archived from the original on 13 May 2013. Retrieved 13 January 2012.

bmj.com (Global: 1,341^st place; English: 1,425^th place)

jnnp.bmj.com

Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D (June 1987). "Gabapentin as an antiepileptic drug in man". Journal of Neurology, Neurosurgery, and Psychiatry. 50 (6): 682–686. doi:10.1136/jnnp.50.6.682. PMC 1032070. PMID 3302110.

books.google.com (Global: 3^rd place; English: 3^rd place)

Pitkänen A, Schwartzkroin PA, Moshé SL (2005). Models of Seizures and Epilepsy. Burlington: Elsevier. p. 539. ISBN 978-0-08-045702-4. Archived from the original on 8 September 2017.
Reed D (2 March 2012). The Other End of the Stethoscope: The Physician's Perspective on the Health Care Crisis. AuthorHouse. pp. 63–. ISBN 978-1-4685-4410-7.
Sobel SV (5 November 2012). Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission. W. W. Norton. p. 124. ISBN 978-0-393-70857-8. Archived from the original on 6 January 2016.
Kaye AD (5 June 2017). Pharmacology, An Issue of Anesthesiology Clinics E-Book. Elsevier Health Sciences. pp. 98–. ISBN 978-0-323-52998-3.
Wyllie E, Cascino GD, Gidal BE, Goodkin HP (17 February 2012). Wyllie's Treatment of Epilepsy: Principles and Practice. Lippincott Williams & Wilkins. p. 423. ISBN 978-1-4511-5348-4.
Benzon H, Rathmell JP, Wu CL, Turk DC, Argoff CE, Hurley RW (11 September 2013). Practical Management of Pain. Elsevier Health Sciences. p. 1006. ISBN 978-0-323-17080-2.
Sneader W (2005). Drug Discovery: A History. John Wiley & Sons. pp. 219–220. ISBN 978-0-470-01552-0.
Johnson DS, Li JJ (26 February 2013). The Art of Drug Synthesis. John Wiley & Sons. pp. 13–. ISBN 978-1-118-67846-6.

businessweek.com (Global: 945^th place; English: 628^th place)

"Pfizer faces $142M in damages for drug fraud". Bloomberg Businessweek. 25 March 2010. Archived from the original on 19 October 2015. Retrieved 13 January 2012.

businesswire.com (Global: 828^th place; English: 485^th place)

"Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.

cbsnews.com (Global: 136^th place; English: 93^rd place)

Pelley S, ed. (7 December 2007). "Prescription For Addiction". 60 Minutes.

clincalc.com (Global: 5,833^rd place; English: 4,432^nd place)

"The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Gabapentin Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 17 August 2025.

dallasnews.com (Global: 903^rd place; English: 457^th place)

Ramshaw E (20 January 2008). "Texas' Prometa program for treating meth addicts draws skeptics". Dallas Morning News. Archived from the original on 27 October 2010.

doi.org (Global: 2^nd place; English: 2^nd place)

Tran KT, Hranicky D, Lark T, Jacob NJ (June 2005). "Gabapentin withdrawal syndrome in the presence of a taper". Bipolar Disorders. 7 (3): 302–4. doi:10.1111/j.1399-5618.2005.00200.x. PMID 15898970.
Schifano F (June 2014). "Misuse and abuse of pregabalin and gabapentin: cause for concern?". CNS Drugs. 28 (6): 491–496. doi:10.1007/s40263-014-0164-4. PMID 24760436.
Goa KL, Sorkin EM (September 1993). "Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy". Drugs. 46 (3): 409–427. doi:10.2165/00003495-199346030-00007. PMID 7693432. S2CID 265753780.
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. (September 2010). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". European Journal of Neurology. 17 (9): 1113–1e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID 20402746. S2CID 14236933.
Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. (June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (6) CD007938. doi:10.1002/14651858.CD007938.pub4. hdl:10044/1/52908. PMC 6452908. PMID 28597471.
Risher WC, Eroglu C (August 2020). "Emerging roles for α2δ subunits in calcium channel function and synaptic connectivity". Current Opinion in Neurobiology. 63: 162–169. doi:10.1016/j.conb.2020.04.007. PMC 7483897. PMID 32521436.
Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A (June 2013). "The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?". Trends in Pharmacological Sciences. 34 (6): 332–339. doi:10.1016/j.tips.2013.04.001. PMID 23642658.
Taylor CP, Harris EW (July 2020). "Analgesia with Gabapentin and Pregabalin May Involve N-Methyl-d-Aspartate Receptors, Neurexins, and Thrombospondins". The Journal of Pharmacology and Experimental Therapeutics. 374 (1): 161–174. doi:10.1124/jpet.120.266056. PMID 32321743. S2CID 216082872.
Gibbons RD, Hur K, Brown CH, Mann JJ (October 2010). "Gabapentin and suicide attempts". Pharmacoepidemiology and Drug Safety. 19 (12). doi:10.1002/pds.2036. PMC 2992093. PMID 20922708.
Henney JE (August 2006). "Safeguarding patient welfare: who's in charge?". Annals of Internal Medicine. 145 (4): 305–307. doi:10.7326/0003-4819-145-4-200608150-00013. PMID 16908923. S2CID 39262014.
Montastruc F, Loo SY, Renoux C (November 2018). "Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017". JAMA. 320 (20): 2149–2151. doi:10.1001/jama.2018.12358. PMC 6583557. PMID 30480717.
Goodman CW, Brett AS (May 2019). "A Clinical Overview of Off-label Use of Gabapentinoid Drugs". JAMA Internal Medicine. 179 (5): 695–701. doi:10.1001/jamainternmed.2019.0086. PMID 30907944. S2CID 85497732.
"Review finds little evidence to support gabapentinoid use in bipolar disorder or insomnia". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 17 October 2022. doi:10.3310/nihrevidence_54173. S2CID 252983016.
Hong JS, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. (March 2022). "Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale". Molecular Psychiatry. 27 (3): 1339–1349. doi:10.1038/s41380-021-01386-6. PMC 9095464. PMID 34819636.
Mayo-Wilson E, Qureshi R, Hong H, Chen X, Li T (December 2023). "Harms were detected but not reported in six clinical trials of gabapentin". Journal of Clinical Epidemiology. 164: 76–87. doi:10.1016/j.jclinepi.2023.10.014. PMID 37871835.
Johannessen SI, Ben-Menachem E (2006). "Management of focal-onset seizures: an update on drug treatment". Drugs. 66 (13): 1701–1725. doi:10.2165/00003495-200666130-00004. PMID 16978035. S2CID 46952737.
Rheims S, Ryvlin P (July 2014). "Pharmacotherapy for tonic-clonic seizures". Expert Opinion on Pharmacotherapy. 15 (10): 1417–1426. doi:10.1517/14656566.2014.915029. PMID 24798217. S2CID 6943460.
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. (2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society". Pain Research & Management. 12 (1): 13–21. doi:10.1155/2007/730785. PMC 2670721. PMID 17372630.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. (February 2015). "Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis". The Lancet. Neurology. 14 (2): 162–173. doi:10.1016/S1474-4422(14)70251-0. PMC 4493167. PMID 25575710.
Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, et al. (August 2017). "Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials". PLOS Medicine. 14 (8) e1002369. doi:10.1371/journal.pmed.1002369. PMC 5557428. PMID 28809936.
Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. (July 2018). "Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis". CMAJ. 190 (26): E786–E793. doi:10.1503/cmaj.171333. PMC 6028270. PMID 29970367.
Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS (December 2010). "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials". PLOS ONE. 5 (12) e14433. Bibcode:2010PLoSO...514433P. doi:10.1371/journal.pone.0014433. PMC 3010990. PMID 21203440.
Moore A, Derry S, Wiffen P (February 2018). "Gabapentin for Chronic Neuropathic Pain". JAMA. 319 (8): 818–819. doi:10.1001/jama.2017.21547. PMID 29486015.
Mula M, Pini S, Cassano GB (June 2007). "The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence". Journal of Clinical Psychopharmacology. 27 (3): 263–272. doi:10.1097/jcp.0b013e318059361a. PMID 17502773. S2CID 38188832.
Greenblatt HK, Greenblatt DJ (March 2018). "Gabapentin and Pregabalin for the Treatment of Anxiety Disorders". Clinical Pharmacology in Drug Development. 7 (3): 228–232. doi:10.1002/cpdd.446. PMID 29579375. S2CID 4321472.
Liu GJ, Karim MR, Xu LL, Wang SL, Yang C, Ding L, et al. (2017). "Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis". Frontiers in Neurology. 8 316. doi:10.3389/fneur.2017.00316. PMC 5510619. PMID 28769860.
Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS (2010). "Treatment effects of gabapentin for primary insomnia". Clinical Neuropharmacology. 33 (2): 84–90. doi:10.1097/WNF.0b013e3181cda242. PMID 20124884. S2CID 4046961.
Berlin RK, Butler PM, Perloff MD (2015). "Gabapentin Therapy in Psychiatric Disorders: A Systematic Review". The Primary Care Companion for CNS Disorders. 17 (5). doi:10.4088/PCC.15r01821. PMC 4732322. PMID 26835178.
Ahmed S, Stanciu CN, Kotapati PV, Ahmed R, Bhivandkar S, Khan AM, et al. (August 2019). "Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review". The Primary Care Companion for CNS Disorders. 21 (4). doi:10.4088/PCC.19r02465. PMID 31461226. S2CID 201662179.
Kranzler HR, Feinn R, Morris P, Hartwell EE (September 2019). "A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder". Addiction. 114 (9): 1547–1555. doi:10.1111/add.14655. PMC 6682454. PMID 31077485.
Mason BJ, Quello S, Shadan F (January 2018). "Gabapentin for the treatment of alcohol use disorder". Expert Opinion on Investigational Drugs. 27 (1): 113–124. doi:10.1080/13543784.2018.1417383. PMC 5957503. PMID 29241365.
Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, et al. (March 2010). "Gabapentin for smoking cessation". Nicotine & Tobacco Research. 12 (3): 300–304. doi:10.1093/ntr/ntp195. PMC 2825098. PMID 20081039.
Nielsen S, Gowing L, Sabioni P, Le Foll B (January 2019). "Pharmacotherapies for cannabis dependence". The Cochrane Database of Systematic Reviews. 1 (1) CD008940. doi:10.1002/14651858.CD008940.pub3. PMC 6360924. PMID 30687936.
McLean RJ, Gottlob I (August 2009). "The pharmacological treatment of nystagmus: a review". Expert Opinion on Pharmacotherapy. 10 (11): 1805–1816. doi:10.1517/14656560902978446. PMID 19601699. S2CID 21477128.
Thurtell MJ, Leigh RJ (February 2012). "Treatment of nystagmus". Current Treatment Options in Neurology. 14 (1): 60–72. doi:10.1007/s11940-011-0154-5. PMID 22072056. S2CID 40370476.
Mehta AR, Kennard C (June 2012). "The pharmacological treatment of acquired nystagmus". Practical Neurology. 12 (3): 147–153. doi:10.1136/practneurol-2011-000181. PMID 22661344. S2CID 1950738.
Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J (June 2020). "Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis". American Journal of Obstetrics and Gynecology. 222 (6): 564–579.e12. doi:10.1016/j.ajog.2019.12.011. PMID 31870736. S2CID 209462426.
Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, et al. (October 2016). "Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper". Multiple Sclerosis. 22 (11): 1386–1396. doi:10.1177/1352458516643600. PMID 27207462. S2CID 25028259.
Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. (July 2018). "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)^§". Movement Disorders. 33 (7): 1077–1091. doi:10.1002/mds.27260. PMID 29756335. S2CID 21669996.
Berger TG, Steinhoff M (June 2011). "Pruritus and renal failure". Seminars in Cutaneous Medicine and Surgery. 30 (2): 99–100. doi:10.1016/j.sder.2011.04.005 (inactive 12 July 2025). PMC 3692272. PMID 21767770.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Hercz D, Jiang SH, Webster AC (December 2020). "Interventions for itch in people with advanced chronic kidney disease". The Cochrane Database of Systematic Reviews. 2020 (12) CD011393. doi:10.1002/14651858.CD011393.pub2. PMC 8094883. PMID 33283264.
Anand S (March 2013). "Gabapentin for pruritus in palliative care". The American Journal of Hospice & Palliative Care. 30 (2): 192–196. doi:10.1177/1049909112445464. PMID 22556282. S2CID 39737885.
Schneider SA, Deuschl G (January 2014). "The treatment of tremor". Neurotherapeutics. 11 (1): 128–138. doi:10.1007/s13311-013-0230-5. PMC 3899476. PMID 24142589.
Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, et al. (November 2011). "Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology". Neurology. 77 (19): 1752–1755. doi:10.1212/WNL.0b013e318236f0fd. PMC 3208950. PMID 22013182.
Sadeghi R, Ondo WG (December 2010). "Pharmacological management of essential tremor". Drugs. 70 (17): 2215–2228. doi:10.2165/11538180-000000000-00000. PMID 21080739. S2CID 10662268.
Ng QX, Han MX, Teoh SE, Yaow CY, Lim YL, Chee KT (August 2021). "A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder". Pharmaceuticals. 14 (9): 834. doi:10.3390/ph14090834. PMC 8469561. PMID 34577534.
Tran DQ, Duong S, Bertini P, Finlayson RJ (February 2010). "Treatment of complex regional pain syndrome: a review of the evidence". Canadian Journal of Anaesthesia. 57 (2): 149–166. doi:10.1007/s12630-009-9237-0. PMID 20054678.
Hamilton TW, Strickland LH, Pandit HG (August 2016). "A Meta-Analysis on the Use of Gabapentinoids for the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty". The Journal of Bone and Joint Surgery. American Volume. 98 (16): 1340–1350. doi:10.2106/jbjs.15.01202. PMID 27535436. Archived from the original on 29 September 2020. Retrieved 22 August 2020.
Aazh H, El Refaie A, Humphriss R (December 2011). "Gabapentin for tinnitus: a systematic review". American Journal of Audiology. 20 (2): 151–158. doi:10.1044/1059-0889(2011/10-0041). PMID 21940981.
Linde M, Mulleners WM, Chronicle EP, McCrory DC (June 2013). "Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults". The Cochrane Database of Systematic Reviews. 2013 (6) CD010609. doi:10.1002/14651858.CD010609. PMC 6599858. PMID 23797675.
Kawalec P, Cierniak A, Pilc A, Nowak G (April 2015). "Pregabalin for the treatment of social anxiety disorder". Expert Opinion on Investigational Drugs. 24 (4): 585–594. doi:10.1517/13543784.2014.979283. PMID 25361817.
Dutta D, Mohindra R, Kumar M, Banerjee M, Sharma M, Mukhopadhyay S (April 2025). "Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review". Indian J Med Res. 161 (4) 363: 363–374. doi:10.25259/IJMR_1990_2024. PMC 12178190. PMID 40536375.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. (February 2015). "Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 100 (2): 363–370. doi:10.1210/jc.2014-3421. PMC 5393509. PMID 25590213.
Yang Y, Wang X (January 2016). "Sexual dysfunction related to antiepileptic drugs in patients with epilepsy". Expert Opinion on Drug Safety. 15 (1): 31–42. doi:10.1517/14740338.2016.1112376. PMID 26559937. S2CID 39571068.
Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY (November 2017). "Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review". Journal of the Neurological Sciences. 382: 36–39. doi:10.1016/j.jns.2017.09.019. PMID 29111014. S2CID 32010921.
Desai A, Kherallah Y, Szabo C, Marawar R (March 2019). "Gabapentin or pregabalin induced myoclonus: A case series and literature review". Journal of Clinical Neuroscience. 61: 225–234. doi:10.1016/j.jocn.2018.09.019. PMID 30381161. S2CID 53165515.
Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. (April 2010). "Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death". JAMA. 303 (14): 1401–1409. doi:10.1001/jama.2010.410. PMID 20388896.
Leith WM, Lambert WE, Boehnlein JK, Freeman MD (January 2019). "The association between gabapentin and suicidality in bipolar patients". International Clinical Psychopharmacology. 34 (1): 27–32. doi:10.1097/YIC.0000000000000242. PMID 30383553. S2CID 54130760.
Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S (June 2019). "Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden". BMJ (Clinical Research Ed.). 365 l2147. doi:10.1136/bmj.l2147. PMC 6559335. PMID 31189556.
Gibbons, R., Hur, K., Lavigne, J., Wang, J., & Mann, J. J. (2019). Medications and Suicide: High Dimensional Empirical Bayes Screening (iDEAS). Harvard Data Science Review, 1(2). https://doi.org/10.1162/99608f92.6fdaa9de
Rahman AA, Dell'Aniello S, Moodie EE, Durand M, Coulombe J, Boivin JF, et al. (January 2024). "Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study". Annals of Internal Medicine. 177 (Online ahead of print): 144–154. doi:10.7326/M23-0849. PMID 38224592. S2CID 266985259.
Mersfelder TL, Nichols WH (March 2016). "Gabapentin: Abuse, Dependence, and Withdrawal". The Annals of Pharmacotherapy. 50 (3): 229–233. doi:10.1177/1060028015620800. PMID 26721643. S2CID 21108959.
Bonnet U, Scherbaum N (December 2017). "How addictive are gabapentin and pregabalin? A systematic review". European Neuropsychopharmacology. 27 (12): 1185–1215. doi:10.1016/j.euroneuro.2017.08.430. PMID 28988943. S2CID 10345555.
Bonnet U, Richter EL, Isbruch K, Scherbaum N (June 2018). "On the addictive power of gabapentinoids: a mini-review" (PDF). Psychiatria Danubina. 30 (2): 142–149. doi:10.24869/psyd.2018.142. PMID 29930223. S2CID 49344251.
Nwankwo A, Koyyalagunta D, Huh B, D'Souza RS, Javed S (November 2024). "A comprehensive review of the typical and atypical side effects of gabapentin". Pain Practice. 24 (8): 1051–1058. doi:10.1111/papr.13400. PMID 38949515.
Huang YH, Pan MH, Yang HI (2023). "The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan". Frontiers in Pharmacology. 14 1128601. doi:10.3389/fphar.2023.1128601. PMC 10266423. PMID 37324474.
Athavale A, Murnion B (December 2023). "Gabapentinoids: a therapeutic review". Australian Prescriber. 46 (4): 80–85. doi:10.18773/austprescr.2023.025. PMC 10751078. PMID 38152314.
Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, et al. (March 2006). "Activity profile of pregabalin in rodent models of epilepsy and ataxia". Epilepsy Research. 68 (3): 189–205. doi:10.1016/j.eplepsyres.2005.11.001. PMID 16337109.
Cheng JK, Chiou LC (2006). "Mechanisms of the antinociceptive action of gabapentin". Journal of Pharmacological Sciences. 100 (5): 471–486. doi:10.1254/jphs.CR0050020. PMID 16474201.
Sills GJ (February 2006). "The mechanisms of action of gabapentin and pregabalin". Current Opinion in Pharmacology. 6 (1): 108–113. doi:10.1016/j.coph.2005.11.003. PMID 16376147.
Calandre EP, Rico-Villademoros F, Slim M (November 2016). "Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Review of Neurotherapeutics. 16 (11): 1263–1277. doi:10.1080/14737175.2016.1202764. PMID 27345098. S2CID 33200190.
Dooley DJ, Taylor CP, Donevan S, Feltner D (February 2007). "Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission". Trends in Pharmacological Sciences. 28 (2): 75–82. doi:10.1016/j.tips.2006.12.006. PMID 17222465.
Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC (May 2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels". Trends in Pharmacological Sciences. 28 (5): 220–228. doi:10.1016/j.tips.2007.03.005. PMID 17403543.
Manville RW, Abbott GW (October 2018). "Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels". Molecular Pharmacology. 94 (4): 1155–1163. doi:10.1124/mol.118.112953. PMC 6108572. PMID 30021858.
Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL (September 1995). "Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA". Epilepsy Research. 22 (1): 1–11. doi:10.1016/0920-1211(95)00028-9. PMID 8565962.
Grankvist N, Lagerborg KA, Jain M, Nilsson R (December 2018). "Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1)". Biochemistry. 57 (49): 6762–6766. doi:10.1021/acs.biochem.8b01031. PMC 6528808. PMID 30427175.
del Amo EM, Urtti A, Yliperttula M (October 2008). "Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2". European Journal of Pharmaceutical Sciences. 35 (3): 161–174. doi:10.1016/j.ejps.2008.06.015. PMID 18656534.
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (October 2010). "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin". Clinical Pharmacokinetics. 49 (10): 661–669. doi:10.2165/11536200-000000000-00000. PMID 20818832. S2CID 16398062.
Dickens D, Webb SD, Antonyuk S, Giannoudis A, Owen A, Rädisch S, et al. (June 2013). "Transport of gabapentin by LAT1 (SLC7A5)". Biochemical Pharmacology. 85 (11): 1672–1683. doi:10.1016/j.bcp.2013.03.022. PMID 23567998.
Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR (2015). "Molecular determinants of blood-brain barrier permeation". Therapeutic Delivery. 6 (8): 961–971. doi:10.4155/tde.15.32. PMC 4675962. PMID 26305616.
Müller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chemistry & Biodiversity. 6 (11): 2071–2083. doi:10.1002/cbdv.200900114. PMID 19937841. S2CID 32513471.
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM (October 1999). "Selective expression of the large neutral amino acid transporter at the blood-brain barrier". Proceedings of the National Academy of Sciences of the United States of America. 96 (21): 12079–12084. Bibcode:1999PNAS...9612079B. doi:10.1073/pnas.96.21.12079. PMC 18415. PMID 10518579.
Ma J, Björnsson ES, Chalasani N (February 2024). "The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review". Am J Med. 137 (2): 99–106. doi:10.1016/j.amjmed.2023.10.022. PMID 37918778. S2CID 264888110.
Agarwal P, Griffith A, Costantino HR, Vaish N (May 2010). "Gabapentin enacarbil - clinical efficacy in restless legs syndrome". Neuropsychiatric Disease and Treatment. 6: 151–158. doi:10.2147/NDT.S5712. PMC 2874339. PMID 20505847.
Levandovskiy IA, Sharapa DI, Shamota TV, Rodionov VN, Shubina TE (February 2011). "Conformationally restricted GABA analogs: from rigid carbocycles to cage hydrocarbons". Future Medicinal Chemistry. 3 (2): 223–241. doi:10.4155/fmc.10.287. PMID 21428817.
Chen Z, Mondal A, Minor DL (June 2023). "Structural basis for Ca_Vα₂δ:gabapentin binding". Nature Structural & Molecular Biology. 30 (6): 735–739. doi:10.1038/s41594-023-00951-7. PMC 10896480. PMID 36973510.
Reimann W (October 1983). "Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action?". European Journal of Pharmacology. 94 (3–4): 341–344. doi:10.1016/0014-2999(83)90425-9. PMID 6653664.
Prevo AJ, Slootman HJ, Harlaar J, Vogelaar TW (1985). "A new antispastic agent: gabapentin: its effect on EMG analysis during voluntary movement in hemiplegia". Clinical Neurophysiology. 62 (3): S221. doi:10.1016/0013-4694(85)90838-7.
Wessely P, Baumgartner C, Klingler D, Kreczi J, Meyerson N, Sailer L, et al. (1987). "Preliminary Results Of A Double Blind Study With The New Migraine Prophylactic Drug Gabapentin". Cephalalgia. 7 (6_suppl): 477–478. doi:10.1177/03331024870070S6214. ISSN 0333-1024.
Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D (June 1987). "Gabapentin as an antiepileptic drug in man". Journal of Neurology, Neurosurgery, and Psychiatry. 50 (6): 682–686. doi:10.1136/jnnp.50.6.682. PMC 1032070. PMID 3302110.
Mack A (2003). "Examination of the evidence for off-label use of gabapentin" (PDF). Journal of Managed Care Pharmacy. 9 (6): 559–568. doi:10.18553/jmcp.2003.9.6.559. PMC 10437292. PMID 14664664. Archived from the original (PDF) on 17 September 2010. Retrieved 15 August 2006.
Irving G (September 2012). "Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians". Therapeutic Advances in Chronic Disease. 3 (5): 211–218. doi:10.1177/2040622312452905. PMC 3539268. PMID 23342236.
Mayor S (October 2018). "Pregabalin and gabapentin become controlled drugs to cut deaths from misuse". BMJ. 363 k4364. doi:10.1136/bmj.k4364. PMID 30327316. S2CID 53520780.
Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, et al. (March 2013). "A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression". The International Journal of Neuropsychopharmacology. 16 (2): 485–496. doi:10.1017/S1461145712000491. PMID 22575611.
"Prometa under fire in Washington drug court program". Alcoholism & Drug Abuse Weekly. 20 (3). 21 January 2008. doi:10.1002/adaw.20121.
Ling W, Shoptaw S, Hillhouse M, Bholat MA, Charuvastra C, Heinzerling K, et al. (February 2012). "Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence". Addiction. 107 (2): 361–369. doi:10.1111/j.1360-0443.2011.03619.x. PMC 4122522. PMID 22082089.
Chan AY, Yuen AS, Tsai DH, Lau WC, Jani YH, Hsia Y, et al. (August 2023). "Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study" (PDF). Nature Communications. 14 (1) 5005. Bibcode:2023NatCo..14.5005C. doi:10.1038/s41467-023-40637-8. PMC 10435503. PMID 37591833.
Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (October 2011). "Modeling sleep data for a new drug in development using markov mixed-effects models". Pharmaceutical Research. 28 (10): 2610–2627. doi:10.1007/s11095-011-0490-x. PMID 21681607. S2CID 22241527.
Landmark CJ, Johannessen SI (February 2008). "Modifications of antiepileptic drugs for improved tolerability and efficacy". Perspectives in Medicinal Chemistry. 2 1177391X0800200001: 21–39. doi:10.1177/1177391X0800200001. PMC 2746576. PMID 19787095.
Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J (August 2012). "Substance misuse of gabapentin". The British Journal of General Practice. 62 (601): 406–407. doi:10.3399/bjgp12X653516. PMC 3404313. PMID 22867659.
Martinez GM, Olabisi J, Ruekert L, Hasan S (July 2019). "A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report". Journal of Psychiatric Practice. 25 (4): 308–312. doi:10.1097/PRA.0000000000000403. PMID 31291212. S2CID 195878855.
Goodman CW, Brett AS (August 2017). "Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?". The New England Journal of Medicine. 377 (5): 411–414. doi:10.1056/NEJMp1704633. PMID 28767350.
Evoy KE, Morrison MD, Saklad SR (March 2017). "Abuse and Misuse of Pregabalin and Gabapentin". Drugs. 77 (4): 403–426. doi:10.1007/s40265-017-0700-x. PMID 28144823. S2CID 24396685.
Bonnet U, Scherbaum N (February 2018). "[On the risk of dependence on gabapentinoids]". Fortschritte der Neurologie-Psychiatrie (in German). 86 (2): 82–105. doi:10.1055/s-0043-122392. PMID 29179227.
Reynolds K, Kaufman R, Korenoski A, Fennimore L, Shulman J, Lynch M (July 2020). "Trends in gabapentin and baclofen exposures reported to U.S. poison centers". Clinical Toxicology. 58 (7): 763–772. doi:10.1080/15563650.2019.1687902. PMID 31786961. S2CID 208537638.
Faryar KA, Webb AN, Bhandari B, Price TG, Bosse GM (June 2019). "Trending gabapentin exposures in Kentucky after legislation requiring the use of the state prescription drug monitoring program for all opioid prescriptions". Clinical Toxicology. 57 (6): 398–403. doi:10.1080/15563650.2018.1538518. PMID 30676102. S2CID 59226292.
Smith RV, Havens JR, Walsh SL (July 2016). "Gabapentin misuse, abuse and diversion: a systematic review". Addiction. 111 (7): 1160–1174. doi:10.1111/add.13324. PMC 5573873. PMID 27265421.
Vettorato E, Corletto F (September 2011). "Gabapentin as part of multi-modal analgesia in two cats suffering multiple injuries". Veterinary Anaesthesia and Analgesia. 38 (5): 518–520. doi:10.1111/j.1467-2995.2011.00638.x. PMID 21831060.
van Haaften KA, Forsythe LR, Stelow EA, Bain MJ (November 2017). "Effects of a single preappointment dose of gabapentin on signs of stress in cats during transportation and veterinary examination". Journal of the American Veterinary Medical Association. 251 (10): 1175–1181. doi:10.2460/javma.251.10.1175. PMID 29099247. S2CID 7780988.
Di Cesare F, Negro V, Ravasio G, Villa R, Draghi S, Cagnardi P (June 2023). "Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses". Animals. 13 (12): 2045. doi:10.3390/ani13122045. PMC 10295034. PMID 37370556.
Kirby-Madden T, Waring CT, Herron M (May 2024). "Effects of Gabapentin on the Treatment of Behavioral Disorders in Dogs: A Retrospective Evaluation". Animals. 14 (10): 1462. doi:10.3390/ani14101462. PMC 11117262. PMID 38791679.

drugfree.org (Global: low place; English: low place)

"Prometa Founder's Spotty Background Explored". 3 November 2006. Archived from the original on 23 September 2015.

drugs.com (Global: 529^th place; English: 550^th place)

"International listings for Gabapentin". Drugs.com. Archived from the original on 16 February 2016. Retrieved 9 February 2016.
"Gabapentin Use During Pregnancy". Drugs.com. 2 December 2019. Retrieved 21 December 2019.
"Gralise Approval History". Drugs.com.

fass.se (Global: low place; English: low place)

"Gabapentin Actavis (Kapsel, hård 300 mg) • FASS text | FASS Vård". Fass.se. Retrieved 8 June 2026.

fda.gov (Global: 470^th place; English: 329^th place)

"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)". U.S. Food and Drug Administration (FDA). 19 December 2019. Archived from the original on 22 December 2019. Retrieved 21 December 2019. This article incorporates text from this source, which is in the public domain.

goodrx.com (Global: low place; English: low place)

Orrange S (31 May 2013). "Yabba Dabba Gabapentin: Are Gralise and Horizant Worth the Cost?". GoodRx, Inc. Archived from the original on 23 June 2018. Retrieved 22 June 2018.

gov.uk (Global: 401^st place; English: 228^th place)

"Pregabalin and gabapentin: proposal to schedule under the Misuse of Drugs Regulations 2001". GOV.UK. 10 November 2017. Retrieved 2 April 2020.
"Pregabalin and gabapentin to be controlled as Class C drugs". GOV.UK. 15 October 2018. Retrieved 2 April 2020.

hdl.handle.net (Global: 66^th place; English: 34^th place)

Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. (June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (6) CD007938. doi:10.1002/14651858.CD007938.pub4. hdl:10044/1/52908. PMC 6452908. PMID 28597471.

healthcarelawinsights.com (Global: low place; English: low place)

Husgen J (3 October 2013). "Pfizer Appeal Targets Fraudulent Drug Marketing Claims Brought Under Civil RICO Statute". Healthcare Law Insights. Hugh Blackwell.

helmholtz-muenchen.de (Global: low place; English: low place)

push-zb.helmholtz-muenchen.de

Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. (July 2018). "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)^§". Movement Disorders. 33 (7): 1077–1091. doi:10.1002/mds.27260. PMID 29756335. S2CID 21669996.

in.gov.br (Global: 3,835^th place; English: 6,615^th place)

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

justice.gov (Global: 884^th place; English: 477^th place)

"United States V. Terren S. Peizer". www.justice.gov. 1 March 2023.

ktla.com (Global: 5,255^th place; English: 2,760^th place)

"Santa Monica man used anti-insider-trading measure to commit fraud: DOJ". 1 March 2023. Archived from the original on 28 March 2023. Retrieved 30 March 2023.

ky.gov (Global: 2,697^th place; English: 1,238^th place)

pharmacy.ky.gov

"Important Notice: Gabapentin Becomes a Schedule 5 Controlled Substance in Kentucky" (PDF). Kentucky State Board of Pharmacy. March 2017. Archived from the original (PDF) on 4 June 2018. Retrieved 18 June 2018.

mayoclinic.org (Global: 2,191^st place; English: 1,798^th place)

"Gabapentin (Oral Route)". Mayo Clinic. Retrieved 1 June 2025.

medicalnewstoday.com (Global: 3,865^th place; English: 3,829^th place)

Gál K, Holland K (March 2024). Patel A (ed.). "What are the side effects of gabapentin?". Medical News Today. Retrieved 1 June 2025.

medscape.com (Global: 1,078^th place; English: 916^th place)

reference.medscape.com

"Neurontin, Gralise (gabapentin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 16 December 2014. Retrieved 6 April 2014.

nbcnews.com (Global: 156^th place; English: 101^st place)

Huus K (5 February 2007). "Unproven meth, cocaine 'remedy' hits market". NBC News.

nhs.uk (Global: 2,637^th place; English: 2,254^th place)

"Side effects of gabapentin". National Health Service. 16 September 2021. Retrieved 20 January 2024.

nice.org.uk (Global: 4,081^st place; English: 3,905^th place)

"Neuropathic pain in adults: pharmacological management in non-specialist settings". National Institute for Health and Care Excellence (NICE). 20 November 2013. Retrieved 14 December 2020.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Tran KT, Hranicky D, Lark T, Jacob NJ (June 2005). "Gabapentin withdrawal syndrome in the presence of a taper". Bipolar Disorders. 7 (3): 302–4. doi:10.1111/j.1399-5618.2005.00200.x. PMID 15898970.
Schifano F (June 2014). "Misuse and abuse of pregabalin and gabapentin: cause for concern?". CNS Drugs. 28 (6): 491–496. doi:10.1007/s40263-014-0164-4. PMID 24760436.
Goa KL, Sorkin EM (September 1993). "Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy". Drugs. 46 (3): 409–427. doi:10.2165/00003495-199346030-00007. PMID 7693432. S2CID 265753780.
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. (September 2010). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". European Journal of Neurology. 17 (9): 1113–1e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID 20402746. S2CID 14236933.
Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. (June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (6) CD007938. doi:10.1002/14651858.CD007938.pub4. hdl:10044/1/52908. PMC 6452908. PMID 28597471.
Risher WC, Eroglu C (August 2020). "Emerging roles for α2δ subunits in calcium channel function and synaptic connectivity". Current Opinion in Neurobiology. 63: 162–169. doi:10.1016/j.conb.2020.04.007. PMC 7483897. PMID 32521436.
Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A (June 2013). "The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?". Trends in Pharmacological Sciences. 34 (6): 332–339. doi:10.1016/j.tips.2013.04.001. PMID 23642658.
Taylor CP, Harris EW (July 2020). "Analgesia with Gabapentin and Pregabalin May Involve N-Methyl-d-Aspartate Receptors, Neurexins, and Thrombospondins". The Journal of Pharmacology and Experimental Therapeutics. 374 (1): 161–174. doi:10.1124/jpet.120.266056. PMID 32321743. S2CID 216082872.
Gibbons RD, Hur K, Brown CH, Mann JJ (October 2010). "Gabapentin and suicide attempts". Pharmacoepidemiology and Drug Safety. 19 (12). doi:10.1002/pds.2036. PMC 2992093. PMID 20922708.
Henney JE (August 2006). "Safeguarding patient welfare: who's in charge?". Annals of Internal Medicine. 145 (4): 305–307. doi:10.7326/0003-4819-145-4-200608150-00013. PMID 16908923. S2CID 39262014.
Montastruc F, Loo SY, Renoux C (November 2018). "Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017". JAMA. 320 (20): 2149–2151. doi:10.1001/jama.2018.12358. PMC 6583557. PMID 30480717.
Goodman CW, Brett AS (May 2019). "A Clinical Overview of Off-label Use of Gabapentinoid Drugs". JAMA Internal Medicine. 179 (5): 695–701. doi:10.1001/jamainternmed.2019.0086. PMID 30907944. S2CID 85497732.
Hong JS, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. (March 2022). "Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale". Molecular Psychiatry. 27 (3): 1339–1349. doi:10.1038/s41380-021-01386-6. PMC 9095464. PMID 34819636.
Mayo-Wilson E, Qureshi R, Hong H, Chen X, Li T (December 2023). "Harms were detected but not reported in six clinical trials of gabapentin". Journal of Clinical Epidemiology. 164: 76–87. doi:10.1016/j.jclinepi.2023.10.014. PMID 37871835.
Johannessen SI, Ben-Menachem E (2006). "Management of focal-onset seizures: an update on drug treatment". Drugs. 66 (13): 1701–1725. doi:10.2165/00003495-200666130-00004. PMID 16978035. S2CID 46952737.
Rheims S, Ryvlin P (July 2014). "Pharmacotherapy for tonic-clonic seizures". Expert Opinion on Pharmacotherapy. 15 (10): 1417–1426. doi:10.1517/14656566.2014.915029. PMID 24798217. S2CID 6943460.
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. (2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society". Pain Research & Management. 12 (1): 13–21. doi:10.1155/2007/730785. PMC 2670721. PMID 17372630.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. (February 2015). "Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis". The Lancet. Neurology. 14 (2): 162–173. doi:10.1016/S1474-4422(14)70251-0. PMC 4493167. PMID 25575710.
Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, et al. (August 2017). "Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials". PLOS Medicine. 14 (8) e1002369. doi:10.1371/journal.pmed.1002369. PMC 5557428. PMID 28809936.
Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. (July 2018). "Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis". CMAJ. 190 (26): E786–E793. doi:10.1503/cmaj.171333. PMC 6028270. PMID 29970367.
Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS (December 2010). "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials". PLOS ONE. 5 (12) e14433. Bibcode:2010PLoSO...514433P. doi:10.1371/journal.pone.0014433. PMC 3010990. PMID 21203440.
Moore A, Derry S, Wiffen P (February 2018). "Gabapentin for Chronic Neuropathic Pain". JAMA. 319 (8): 818–819. doi:10.1001/jama.2017.21547. PMID 29486015.
Mula M, Pini S, Cassano GB (June 2007). "The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence". Journal of Clinical Psychopharmacology. 27 (3): 263–272. doi:10.1097/jcp.0b013e318059361a. PMID 17502773. S2CID 38188832.
Greenblatt HK, Greenblatt DJ (March 2018). "Gabapentin and Pregabalin for the Treatment of Anxiety Disorders". Clinical Pharmacology in Drug Development. 7 (3): 228–232. doi:10.1002/cpdd.446. PMID 29579375. S2CID 4321472.
Liu GJ, Karim MR, Xu LL, Wang SL, Yang C, Ding L, et al. (2017). "Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis". Frontiers in Neurology. 8 316. doi:10.3389/fneur.2017.00316. PMC 5510619. PMID 28769860.
Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS (2010). "Treatment effects of gabapentin for primary insomnia". Clinical Neuropharmacology. 33 (2): 84–90. doi:10.1097/WNF.0b013e3181cda242. PMID 20124884. S2CID 4046961.
Muncie HL, Yasinian Y, Oge' L (November 2013). "Outpatient management of alcohol withdrawal syndrome". American Family Physician. 88 (9): 589–595. PMID 24364635.
Berlin RK, Butler PM, Perloff MD (2015). "Gabapentin Therapy in Psychiatric Disorders: A Systematic Review". The Primary Care Companion for CNS Disorders. 17 (5). doi:10.4088/PCC.15r01821. PMC 4732322. PMID 26835178.
Ahmed S, Stanciu CN, Kotapati PV, Ahmed R, Bhivandkar S, Khan AM, et al. (August 2019). "Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review". The Primary Care Companion for CNS Disorders. 21 (4). doi:10.4088/PCC.19r02465. PMID 31461226. S2CID 201662179.
Kranzler HR, Feinn R, Morris P, Hartwell EE (September 2019). "A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder". Addiction. 114 (9): 1547–1555. doi:10.1111/add.14655. PMC 6682454. PMID 31077485.
Mason BJ, Quello S, Shadan F (January 2018). "Gabapentin for the treatment of alcohol use disorder". Expert Opinion on Investigational Drugs. 27 (1): 113–124. doi:10.1080/13543784.2018.1417383. PMC 5957503. PMID 29241365.
Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, et al. (March 2010). "Gabapentin for smoking cessation". Nicotine & Tobacco Research. 12 (3): 300–304. doi:10.1093/ntr/ntp195. PMC 2825098. PMID 20081039.
Behnam B, Semnani V, Saghafi N, Ghorbani R, Dianak Shori M, Ghooshchian Choobmasjedi S (2012). "Gabapentin Effect on Pain Associated with Heroin Withdrawal in Iranian Crack: a Randomized Double-blind Clinical Trial". Iranian Journal of Pharmaceutical Research. 11 (3): 979–983. PMC 3813133. PMID 24250527.
Nielsen S, Gowing L, Sabioni P, Le Foll B (January 2019). "Pharmacotherapies for cannabis dependence". The Cochrane Database of Systematic Reviews. 1 (1) CD008940. doi:10.1002/14651858.CD008940.pub3. PMC 6360924. PMID 30687936.
McLean RJ, Gottlob I (August 2009). "The pharmacological treatment of nystagmus: a review". Expert Opinion on Pharmacotherapy. 10 (11): 1805–1816. doi:10.1517/14656560902978446. PMID 19601699. S2CID 21477128.
Thurtell MJ, Leigh RJ (February 2012). "Treatment of nystagmus". Current Treatment Options in Neurology. 14 (1): 60–72. doi:10.1007/s11940-011-0154-5. PMID 22072056. S2CID 40370476.
Mehta AR, Kennard C (June 2012). "The pharmacological treatment of acquired nystagmus". Practical Neurology. 12 (3): 147–153. doi:10.1136/practneurol-2011-000181. PMID 22661344. S2CID 1950738.
Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J (June 2020). "Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis". American Journal of Obstetrics and Gynecology. 222 (6): 564–579.e12. doi:10.1016/j.ajog.2019.12.011. PMID 31870736. S2CID 209462426.
Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, et al. (October 2016). "Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper". Multiple Sclerosis. 22 (11): 1386–1396. doi:10.1177/1352458516643600. PMID 27207462. S2CID 25028259.
Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. (July 2018). "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)^§". Movement Disorders. 33 (7): 1077–1091. doi:10.1002/mds.27260. PMID 29756335. S2CID 21669996.
Berger TG, Steinhoff M (June 2011). "Pruritus and renal failure". Seminars in Cutaneous Medicine and Surgery. 30 (2): 99–100. doi:10.1016/j.sder.2011.04.005 (inactive 12 July 2025). PMC 3692272. PMID 21767770.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Hercz D, Jiang SH, Webster AC (December 2020). "Interventions for itch in people with advanced chronic kidney disease". The Cochrane Database of Systematic Reviews. 2020 (12) CD011393. doi:10.1002/14651858.CD011393.pub2. PMC 8094883. PMID 33283264.
Anand S (March 2013). "Gabapentin for pruritus in palliative care". The American Journal of Hospice & Palliative Care. 30 (2): 192–196. doi:10.1177/1049909112445464. PMID 22556282. S2CID 39737885.
Schneider SA, Deuschl G (January 2014). "The treatment of tremor". Neurotherapeutics. 11 (1): 128–138. doi:10.1007/s13311-013-0230-5. PMC 3899476. PMID 24142589.
Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, et al. (November 2011). "Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology". Neurology. 77 (19): 1752–1755. doi:10.1212/WNL.0b013e318236f0fd. PMC 3208950. PMID 22013182.
Sadeghi R, Ondo WG (December 2010). "Pharmacological management of essential tremor". Drugs. 70 (17): 2215–2228. doi:10.2165/11538180-000000000-00000. PMID 21080739. S2CID 10662268.
Ng QX, Han MX, Teoh SE, Yaow CY, Lim YL, Chee KT (August 2021). "A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder". Pharmaceuticals. 14 (9): 834. doi:10.3390/ph14090834. PMC 8469561. PMID 34577534.
Tran DQ, Duong S, Bertini P, Finlayson RJ (February 2010). "Treatment of complex regional pain syndrome: a review of the evidence". Canadian Journal of Anaesthesia. 57 (2): 149–166. doi:10.1007/s12630-009-9237-0. PMID 20054678.
Hamilton TW, Strickland LH, Pandit HG (August 2016). "A Meta-Analysis on the Use of Gabapentinoids for the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty". The Journal of Bone and Joint Surgery. American Volume. 98 (16): 1340–1350. doi:10.2106/jbjs.15.01202. PMID 27535436. Archived from the original on 29 September 2020. Retrieved 22 August 2020.
Aazh H, El Refaie A, Humphriss R (December 2011). "Gabapentin for tinnitus: a systematic review". American Journal of Audiology. 20 (2): 151–158. doi:10.1044/1059-0889(2011/10-0041). PMID 21940981.
Linde M, Mulleners WM, Chronicle EP, McCrory DC (June 2013). "Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults". The Cochrane Database of Systematic Reviews. 2013 (6) CD010609. doi:10.1002/14651858.CD010609. PMC 6599858. PMID 23797675.
Kawalec P, Cierniak A, Pilc A, Nowak G (April 2015). "Pregabalin for the treatment of social anxiety disorder". Expert Opinion on Investigational Drugs. 24 (4): 585–594. doi:10.1517/13543784.2014.979283. PMID 25361817.
Dutta D, Mohindra R, Kumar M, Banerjee M, Sharma M, Mukhopadhyay S (April 2025). "Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review". Indian J Med Res. 161 (4) 363: 363–374. doi:10.25259/IJMR_1990_2024. PMC 12178190. PMID 40536375.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. (February 2015). "Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 100 (2): 363–370. doi:10.1210/jc.2014-3421. PMC 5393509. PMID 25590213.
Yang Y, Wang X (January 2016). "Sexual dysfunction related to antiepileptic drugs in patients with epilepsy". Expert Opinion on Drug Safety. 15 (1): 31–42. doi:10.1517/14740338.2016.1112376. PMID 26559937. S2CID 39571068.
Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY (November 2017). "Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review". Journal of the Neurological Sciences. 382: 36–39. doi:10.1016/j.jns.2017.09.019. PMID 29111014. S2CID 32010921.
Desai A, Kherallah Y, Szabo C, Marawar R (March 2019). "Gabapentin or pregabalin induced myoclonus: A case series and literature review". Journal of Clinical Neuroscience. 61: 225–234. doi:10.1016/j.jocn.2018.09.019. PMID 30381161. S2CID 53165515.
Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. (April 2010). "Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death". JAMA. 303 (14): 1401–1409. doi:10.1001/jama.2010.410. PMID 20388896.
Leith WM, Lambert WE, Boehnlein JK, Freeman MD (January 2019). "The association between gabapentin and suicidality in bipolar patients". International Clinical Psychopharmacology. 34 (1): 27–32. doi:10.1097/YIC.0000000000000242. PMID 30383553. S2CID 54130760.
Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S (June 2019). "Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden". BMJ (Clinical Research Ed.). 365 l2147. doi:10.1136/bmj.l2147. PMC 6559335. PMID 31189556.
Rahman AA, Dell'Aniello S, Moodie EE, Durand M, Coulombe J, Boivin JF, et al. (January 2024). "Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study". Annals of Internal Medicine. 177 (Online ahead of print): 144–154. doi:10.7326/M23-0849. PMID 38224592. S2CID 266985259.
Mersfelder TL, Nichols WH (March 2016). "Gabapentin: Abuse, Dependence, and Withdrawal". The Annals of Pharmacotherapy. 50 (3): 229–233. doi:10.1177/1060028015620800. PMID 26721643. S2CID 21108959.
Bonnet U, Scherbaum N (December 2017). "How addictive are gabapentin and pregabalin? A systematic review". European Neuropsychopharmacology. 27 (12): 1185–1215. doi:10.1016/j.euroneuro.2017.08.430. PMID 28988943. S2CID 10345555.
Bonnet U, Richter EL, Isbruch K, Scherbaum N (June 2018). "On the addictive power of gabapentinoids: a mini-review" (PDF). Psychiatria Danubina. 30 (2): 142–149. doi:10.24869/psyd.2018.142. PMID 29930223. S2CID 49344251.
Nwankwo A, Koyyalagunta D, Huh B, D'Souza RS, Javed S (November 2024). "A comprehensive review of the typical and atypical side effects of gabapentin". Pain Practice. 24 (8): 1051–1058. doi:10.1111/papr.13400. PMID 38949515.
Huang YH, Pan MH, Yang HI (2023). "The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan". Frontiers in Pharmacology. 14 1128601. doi:10.3389/fphar.2023.1128601. PMC 10266423. PMID 37324474.
Athavale A, Murnion B (December 2023). "Gabapentinoids: a therapeutic review". Australian Prescriber. 46 (4): 80–85. doi:10.18773/austprescr.2023.025. PMC 10751078. PMID 38152314.
Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, et al. (March 2006). "Activity profile of pregabalin in rodent models of epilepsy and ataxia". Epilepsy Research. 68 (3): 189–205. doi:10.1016/j.eplepsyres.2005.11.001. PMID 16337109.
Cheng JK, Chiou LC (2006). "Mechanisms of the antinociceptive action of gabapentin". Journal of Pharmacological Sciences. 100 (5): 471–486. doi:10.1254/jphs.CR0050020. PMID 16474201.
Sills GJ (February 2006). "The mechanisms of action of gabapentin and pregabalin". Current Opinion in Pharmacology. 6 (1): 108–113. doi:10.1016/j.coph.2005.11.003. PMID 16376147.
Calandre EP, Rico-Villademoros F, Slim M (November 2016). "Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Review of Neurotherapeutics. 16 (11): 1263–1277. doi:10.1080/14737175.2016.1202764. PMID 27345098. S2CID 33200190.
Dooley DJ, Taylor CP, Donevan S, Feltner D (February 2007). "Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission". Trends in Pharmacological Sciences. 28 (2): 75–82. doi:10.1016/j.tips.2006.12.006. PMID 17222465.
Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC (May 2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels". Trends in Pharmacological Sciences. 28 (5): 220–228. doi:10.1016/j.tips.2007.03.005. PMID 17403543.
Manville RW, Abbott GW (October 2018). "Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels". Molecular Pharmacology. 94 (4): 1155–1163. doi:10.1124/mol.118.112953. PMC 6108572. PMID 30021858.
Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL (September 1995). "Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA". Epilepsy Research. 22 (1): 1–11. doi:10.1016/0920-1211(95)00028-9. PMID 8565962.
Grankvist N, Lagerborg KA, Jain M, Nilsson R (December 2018). "Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1)". Biochemistry. 57 (49): 6762–6766. doi:10.1021/acs.biochem.8b01031. PMC 6528808. PMID 30427175.
del Amo EM, Urtti A, Yliperttula M (October 2008). "Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2". European Journal of Pharmaceutical Sciences. 35 (3): 161–174. doi:10.1016/j.ejps.2008.06.015. PMID 18656534.
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (October 2010). "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin". Clinical Pharmacokinetics. 49 (10): 661–669. doi:10.2165/11536200-000000000-00000. PMID 20818832. S2CID 16398062.
Dickens D, Webb SD, Antonyuk S, Giannoudis A, Owen A, Rädisch S, et al. (June 2013). "Transport of gabapentin by LAT1 (SLC7A5)". Biochemical Pharmacology. 85 (11): 1672–1683. doi:10.1016/j.bcp.2013.03.022. PMID 23567998.
Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR (2015). "Molecular determinants of blood-brain barrier permeation". Therapeutic Delivery. 6 (8): 961–971. doi:10.4155/tde.15.32. PMC 4675962. PMID 26305616.
Müller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chemistry & Biodiversity. 6 (11): 2071–2083. doi:10.1002/cbdv.200900114. PMID 19937841. S2CID 32513471.
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM (October 1999). "Selective expression of the large neutral amino acid transporter at the blood-brain barrier". Proceedings of the National Academy of Sciences of the United States of America. 96 (21): 12079–12084. Bibcode:1999PNAS...9612079B. doi:10.1073/pnas.96.21.12079. PMC 18415. PMID 10518579.
Ma J, Björnsson ES, Chalasani N (February 2024). "The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review". Am J Med. 137 (2): 99–106. doi:10.1016/j.amjmed.2023.10.022. PMID 37918778. S2CID 264888110.
Agarwal P, Griffith A, Costantino HR, Vaish N (May 2010). "Gabapentin enacarbil - clinical efficacy in restless legs syndrome". Neuropsychiatric Disease and Treatment. 6: 151–158. doi:10.2147/NDT.S5712. PMC 2874339. PMID 20505847.
Levandovskiy IA, Sharapa DI, Shamota TV, Rodionov VN, Shubina TE (February 2011). "Conformationally restricted GABA analogs: from rigid carbocycles to cage hydrocarbons". Future Medicinal Chemistry. 3 (2): 223–241. doi:10.4155/fmc.10.287. PMID 21428817.
Chen Z, Mondal A, Minor DL (June 2023). "Structural basis for Ca_Vα₂δ:gabapentin binding". Nature Structural & Molecular Biology. 30 (6): 735–739. doi:10.1038/s41594-023-00951-7. PMC 10896480. PMID 36973510.
Reimann W (October 1983). "Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action?". European Journal of Pharmacology. 94 (3–4): 341–344. doi:10.1016/0014-2999(83)90425-9. PMID 6653664.
Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D (June 1987). "Gabapentin as an antiepileptic drug in man". Journal of Neurology, Neurosurgery, and Psychiatry. 50 (6): 682–686. doi:10.1136/jnnp.50.6.682. PMC 1032070. PMID 3302110.
Mack A (2003). "Examination of the evidence for off-label use of gabapentin" (PDF). Journal of Managed Care Pharmacy. 9 (6): 559–568. doi:10.18553/jmcp.2003.9.6.559. PMC 10437292. PMID 14664664. Archived from the original (PDF) on 17 September 2010. Retrieved 15 August 2006.
Irving G (September 2012). "Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians". Therapeutic Advances in Chronic Disease. 3 (5): 211–218. doi:10.1177/2040622312452905. PMC 3539268. PMID 23342236.
Mayor S (October 2018). "Pregabalin and gabapentin become controlled drugs to cut deaths from misuse". BMJ. 363 k4364. doi:10.1136/bmj.k4364. PMID 30327316. S2CID 53520780.
Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, et al. (March 2013). "A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression". The International Journal of Neuropsychopharmacology. 16 (2): 485–496. doi:10.1017/S1461145712000491. PMID 22575611.
Ling W, Shoptaw S, Hillhouse M, Bholat MA, Charuvastra C, Heinzerling K, et al. (February 2012). "Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence". Addiction. 107 (2): 361–369. doi:10.1111/j.1360-0443.2011.03619.x. PMC 4122522. PMID 22082089.
Chan AY, Yuen AS, Tsai DH, Lau WC, Jani YH, Hsia Y, et al. (August 2023). "Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study" (PDF). Nature Communications. 14 (1) 5005. Bibcode:2023NatCo..14.5005C. doi:10.1038/s41467-023-40637-8. PMC 10435503. PMID 37591833.
Baillie JK, Power I (January 2006). "The mechanism of action of gabapentin in neuropathic pain". Current Opinion in Investigational Drugs. 7 (1): 33–39. PMID 16425669.
Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (October 2011). "Modeling sleep data for a new drug in development using markov mixed-effects models". Pharmaceutical Research. 28 (10): 2610–2627. doi:10.1007/s11095-011-0490-x. PMID 21681607. S2CID 22241527.
Landmark CJ, Johannessen SI (February 2008). "Modifications of antiepileptic drugs for improved tolerability and efficacy". Perspectives in Medicinal Chemistry. 2 1177391X0800200001: 21–39. doi:10.1177/1177391X0800200001. PMC 2746576. PMID 19787095.
Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J (August 2012). "Substance misuse of gabapentin". The British Journal of General Practice. 62 (601): 406–407. doi:10.3399/bjgp12X653516. PMC 3404313. PMID 22867659.
Martinez GM, Olabisi J, Ruekert L, Hasan S (July 2019). "A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report". Journal of Psychiatric Practice. 25 (4): 308–312. doi:10.1097/PRA.0000000000000403. PMID 31291212. S2CID 195878855.
Goodman CW, Brett AS (August 2017). "Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?". The New England Journal of Medicine. 377 (5): 411–414. doi:10.1056/NEJMp1704633. PMID 28767350.
Evoy KE, Morrison MD, Saklad SR (March 2017). "Abuse and Misuse of Pregabalin and Gabapentin". Drugs. 77 (4): 403–426. doi:10.1007/s40265-017-0700-x. PMID 28144823. S2CID 24396685.
Bonnet U, Scherbaum N (February 2018). "[On the risk of dependence on gabapentinoids]". Fortschritte der Neurologie-Psychiatrie (in German). 86 (2): 82–105. doi:10.1055/s-0043-122392. PMID 29179227.
Reynolds K, Kaufman R, Korenoski A, Fennimore L, Shulman J, Lynch M (July 2020). "Trends in gabapentin and baclofen exposures reported to U.S. poison centers". Clinical Toxicology. 58 (7): 763–772. doi:10.1080/15563650.2019.1687902. PMID 31786961. S2CID 208537638.
Faryar KA, Webb AN, Bhandari B, Price TG, Bosse GM (June 2019). "Trending gabapentin exposures in Kentucky after legislation requiring the use of the state prescription drug monitoring program for all opioid prescriptions". Clinical Toxicology. 57 (6): 398–403. doi:10.1080/15563650.2018.1538518. PMID 30676102. S2CID 59226292.
Smith RV, Havens JR, Walsh SL (July 2016). "Gabapentin misuse, abuse and diversion: a systematic review". Addiction. 111 (7): 1160–1174. doi:10.1111/add.13324. PMC 5573873. PMID 27265421.
Vettorato E, Corletto F (September 2011). "Gabapentin as part of multi-modal analgesia in two cats suffering multiple injuries". Veterinary Anaesthesia and Analgesia. 38 (5): 518–520. doi:10.1111/j.1467-2995.2011.00638.x. PMID 21831060.
van Haaften KA, Forsythe LR, Stelow EA, Bain MJ (November 2017). "Effects of a single preappointment dose of gabapentin on signs of stress in cats during transportation and veterinary examination". Journal of the American Veterinary Medical Association. 251 (10): 1175–1181. doi:10.2460/javma.251.10.1175. PMID 29099247. S2CID 7780988.
Di Cesare F, Negro V, Ravasio G, Villa R, Draghi S, Cagnardi P (June 2023). "Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses". Animals. 13 (12): 2045. doi:10.3390/ani13122045. PMC 10295034. PMID 37370556.
Kirby-Madden T, Waring CT, Herron M (May 2024). "Effects of Gabapentin on the Treatment of Behavioral Disorders in Dogs: A Retrospective Evaluation". Animals. 14 (10): 1462. doi:10.3390/ani14101462. PMC 11117262. PMID 38791679.

ncbi.nlm.nih.gov

Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. (June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (6) CD007938. doi:10.1002/14651858.CD007938.pub4. hdl:10044/1/52908. PMC 6452908. PMID 28597471.
Risher WC, Eroglu C (August 2020). "Emerging roles for α2δ subunits in calcium channel function and synaptic connectivity". Current Opinion in Neurobiology. 63: 162–169. doi:10.1016/j.conb.2020.04.007. PMC 7483897. PMID 32521436.
Gibbons RD, Hur K, Brown CH, Mann JJ (October 2010). "Gabapentin and suicide attempts". Pharmacoepidemiology and Drug Safety. 19 (12). doi:10.1002/pds.2036. PMC 2992093. PMID 20922708.
Montastruc F, Loo SY, Renoux C (November 2018). "Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017". JAMA. 320 (20): 2149–2151. doi:10.1001/jama.2018.12358. PMC 6583557. PMID 30480717.
Hong JS, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. (March 2022). "Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale". Molecular Psychiatry. 27 (3): 1339–1349. doi:10.1038/s41380-021-01386-6. PMC 9095464. PMID 34819636.
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. (2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society". Pain Research & Management. 12 (1): 13–21. doi:10.1155/2007/730785. PMC 2670721. PMID 17372630.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. (February 2015). "Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis". The Lancet. Neurology. 14 (2): 162–173. doi:10.1016/S1474-4422(14)70251-0. PMC 4493167. PMID 25575710.
Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, et al. (August 2017). "Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials". PLOS Medicine. 14 (8) e1002369. doi:10.1371/journal.pmed.1002369. PMC 5557428. PMID 28809936.
Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. (July 2018). "Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis". CMAJ. 190 (26): E786–E793. doi:10.1503/cmaj.171333. PMC 6028270. PMID 29970367.
Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS (December 2010). "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials". PLOS ONE. 5 (12) e14433. Bibcode:2010PLoSO...514433P. doi:10.1371/journal.pone.0014433. PMC 3010990. PMID 21203440.
Liu GJ, Karim MR, Xu LL, Wang SL, Yang C, Ding L, et al. (2017). "Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis". Frontiers in Neurology. 8 316. doi:10.3389/fneur.2017.00316. PMC 5510619. PMID 28769860.
Berlin RK, Butler PM, Perloff MD (2015). "Gabapentin Therapy in Psychiatric Disorders: A Systematic Review". The Primary Care Companion for CNS Disorders. 17 (5). doi:10.4088/PCC.15r01821. PMC 4732322. PMID 26835178.
Kranzler HR, Feinn R, Morris P, Hartwell EE (September 2019). "A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder". Addiction. 114 (9): 1547–1555. doi:10.1111/add.14655. PMC 6682454. PMID 31077485.
Mason BJ, Quello S, Shadan F (January 2018). "Gabapentin for the treatment of alcohol use disorder". Expert Opinion on Investigational Drugs. 27 (1): 113–124. doi:10.1080/13543784.2018.1417383. PMC 5957503. PMID 29241365.
Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, et al. (March 2010). "Gabapentin for smoking cessation". Nicotine & Tobacco Research. 12 (3): 300–304. doi:10.1093/ntr/ntp195. PMC 2825098. PMID 20081039.
Behnam B, Semnani V, Saghafi N, Ghorbani R, Dianak Shori M, Ghooshchian Choobmasjedi S (2012). "Gabapentin Effect on Pain Associated with Heroin Withdrawal in Iranian Crack: a Randomized Double-blind Clinical Trial". Iranian Journal of Pharmaceutical Research. 11 (3): 979–983. PMC 3813133. PMID 24250527.
Nielsen S, Gowing L, Sabioni P, Le Foll B (January 2019). "Pharmacotherapies for cannabis dependence". The Cochrane Database of Systematic Reviews. 1 (1) CD008940. doi:10.1002/14651858.CD008940.pub3. PMC 6360924. PMID 30687936.
Berger TG, Steinhoff M (June 2011). "Pruritus and renal failure". Seminars in Cutaneous Medicine and Surgery. 30 (2): 99–100. doi:10.1016/j.sder.2011.04.005 (inactive 12 July 2025). PMC 3692272. PMID 21767770.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Hercz D, Jiang SH, Webster AC (December 2020). "Interventions for itch in people with advanced chronic kidney disease". The Cochrane Database of Systematic Reviews. 2020 (12) CD011393. doi:10.1002/14651858.CD011393.pub2. PMC 8094883. PMID 33283264.
Schneider SA, Deuschl G (January 2014). "The treatment of tremor". Neurotherapeutics. 11 (1): 128–138. doi:10.1007/s13311-013-0230-5. PMC 3899476. PMID 24142589.
Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, et al. (November 2011). "Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology". Neurology. 77 (19): 1752–1755. doi:10.1212/WNL.0b013e318236f0fd. PMC 3208950. PMID 22013182.
Ng QX, Han MX, Teoh SE, Yaow CY, Lim YL, Chee KT (August 2021). "A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder". Pharmaceuticals. 14 (9): 834. doi:10.3390/ph14090834. PMC 8469561. PMID 34577534.
Linde M, Mulleners WM, Chronicle EP, McCrory DC (June 2013). "Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults". The Cochrane Database of Systematic Reviews. 2013 (6) CD010609. doi:10.1002/14651858.CD010609. PMC 6599858. PMID 23797675.
Dutta D, Mohindra R, Kumar M, Banerjee M, Sharma M, Mukhopadhyay S (April 2025). "Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review". Indian J Med Res. 161 (4) 363: 363–374. doi:10.25259/IJMR_1990_2024. PMC 12178190. PMID 40536375.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. (February 2015). "Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 100 (2): 363–370. doi:10.1210/jc.2014-3421. PMC 5393509. PMID 25590213.
Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S (June 2019). "Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden". BMJ (Clinical Research Ed.). 365 l2147. doi:10.1136/bmj.l2147. PMC 6559335. PMID 31189556.
Huang YH, Pan MH, Yang HI (2023). "The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan". Frontiers in Pharmacology. 14 1128601. doi:10.3389/fphar.2023.1128601. PMC 10266423. PMID 37324474.
Athavale A, Murnion B (December 2023). "Gabapentinoids: a therapeutic review". Australian Prescriber. 46 (4): 80–85. doi:10.18773/austprescr.2023.025. PMC 10751078. PMID 38152314.
Manville RW, Abbott GW (October 2018). "Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels". Molecular Pharmacology. 94 (4): 1155–1163. doi:10.1124/mol.118.112953. PMC 6108572. PMID 30021858.
Grankvist N, Lagerborg KA, Jain M, Nilsson R (December 2018). "Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1)". Biochemistry. 57 (49): 6762–6766. doi:10.1021/acs.biochem.8b01031. PMC 6528808. PMID 30427175.
Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR (2015). "Molecular determinants of blood-brain barrier permeation". Therapeutic Delivery. 6 (8): 961–971. doi:10.4155/tde.15.32. PMC 4675962. PMID 26305616.
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM (October 1999). "Selective expression of the large neutral amino acid transporter at the blood-brain barrier". Proceedings of the National Academy of Sciences of the United States of America. 96 (21): 12079–12084. Bibcode:1999PNAS...9612079B. doi:10.1073/pnas.96.21.12079. PMC 18415. PMID 10518579.
Agarwal P, Griffith A, Costantino HR, Vaish N (May 2010). "Gabapentin enacarbil - clinical efficacy in restless legs syndrome". Neuropsychiatric Disease and Treatment. 6: 151–158. doi:10.2147/NDT.S5712. PMC 2874339. PMID 20505847.
Chen Z, Mondal A, Minor DL (June 2023). "Structural basis for Ca_Vα₂δ:gabapentin binding". Nature Structural & Molecular Biology. 30 (6): 735–739. doi:10.1038/s41594-023-00951-7. PMC 10896480. PMID 36973510.
Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D (June 1987). "Gabapentin as an antiepileptic drug in man". Journal of Neurology, Neurosurgery, and Psychiatry. 50 (6): 682–686. doi:10.1136/jnnp.50.6.682. PMC 1032070. PMID 3302110.
Mack A (2003). "Examination of the evidence for off-label use of gabapentin" (PDF). Journal of Managed Care Pharmacy. 9 (6): 559–568. doi:10.18553/jmcp.2003.9.6.559. PMC 10437292. PMID 14664664. Archived from the original (PDF) on 17 September 2010. Retrieved 15 August 2006.
Irving G (September 2012). "Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians". Therapeutic Advances in Chronic Disease. 3 (5): 211–218. doi:10.1177/2040622312452905. PMC 3539268. PMID 23342236.
Ling W, Shoptaw S, Hillhouse M, Bholat MA, Charuvastra C, Heinzerling K, et al. (February 2012). "Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence". Addiction. 107 (2): 361–369. doi:10.1111/j.1360-0443.2011.03619.x. PMC 4122522. PMID 22082089.
Chan AY, Yuen AS, Tsai DH, Lau WC, Jani YH, Hsia Y, et al. (August 2023). "Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study" (PDF). Nature Communications. 14 (1) 5005. Bibcode:2023NatCo..14.5005C. doi:10.1038/s41467-023-40637-8. PMC 10435503. PMID 37591833.
Landmark CJ, Johannessen SI (February 2008). "Modifications of antiepileptic drugs for improved tolerability and efficacy". Perspectives in Medicinal Chemistry. 2 1177391X0800200001: 21–39. doi:10.1177/1177391X0800200001. PMC 2746576. PMID 19787095.
Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J (August 2012). "Substance misuse of gabapentin". The British Journal of General Practice. 62 (601): 406–407. doi:10.3399/bjgp12X653516. PMC 3404313. PMID 22867659.
Smith RV, Havens JR, Walsh SL (July 2016). "Gabapentin misuse, abuse and diversion: a systematic review". Addiction. 111 (7): 1160–1174. doi:10.1111/add.13324. PMC 5573873. PMID 27265421.
Di Cesare F, Negro V, Ravasio G, Villa R, Draghi S, Cagnardi P (June 2023). "Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses". Animals. 13 (12): 2045. doi:10.3390/ani13122045. PMC 10295034. PMID 37370556.
Kirby-Madden T, Waring CT, Herron M (May 2024). "Effects of Gabapentin on the Treatment of Behavioral Disorders in Dogs: A Retrospective Evaluation". Animals. 14 (10): 1462. doi:10.3390/ani14101462. PMC 11117262. PMID 38791679.

dailymed.nlm.nih.gov

"Neurontin- gabapentin capsule Neurontin- gabapentin tablet, film coated Neurontin- gabapentin solution". DailyMed. 11 April 2019. Retrieved 21 December 2019.

nihr.ac.uk (Global: low place; English: 7,409^th place)

evidence.nihr.ac.uk

"Review finds little evidence to support gabapentinoid use in bipolar disorder or insomnia". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 17 October 2022. doi:10.3310/nihrevidence_54173. S2CID 252983016.

nursingnotes.co.uk (Global: low place; English: low place)

"Pregabalin and gabapentin will become controlled drugs in April". NursingNotes. 17 October 2018. Archived from the original on 16 June 2019. Retrieved 16 June 2019.

nytimes.com (Global: 7^th place; English: 7^th place)

Span P (17 August 2024). "The Painkiller Used for Just About Anything". The New York Times. Retrieved 21 December 2024.

osf.io (Global: 8,809^th place; English: 5,705^th place)

Mayo-Wilson E, Qureshi R, Hong H, Chen X, Li T (December 2023). "Harms were detected but not reported in six clinical trials of gabapentin". Journal of Clinical Epidemiology. 164: 76–87. doi:10.1016/j.jclinepi.2023.10.014. PMID 37871835.

ox.ac.uk (Global: 541^st place; English: 356^th place)

ora.ox.ac.uk

Hamilton TW, Strickland LH, Pandit HG (August 2016). "A Meta-Analysis on the Use of Gabapentinoids for the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty". The Journal of Bone and Joint Surgery. American Volume. 98 (16): 1340–1350. doi:10.2106/jbjs.15.01202. PMID 27535436. Archived from the original on 29 September 2020. Retrieved 22 August 2020.

patents.google.com (Global: 1,154^th place; English: 606^th place)

Kumar A, Soudagar SR, Nijasure AM, Panda NB, Gautam P, Thakur GR. "Process For Synthesis Of Gabapentin".
US4024175A, Satzinger G, Hartenstein J, Herrmann M, Heldt W, "Cyclic amino acids", issued 17 May 1977

pfizer.com (Global: low place; English: low place)

"Neurontin". Pfizer. Retrieved 17 June 2024.

plumbsveterinarydrugs.com (Global: low place; English: low place)

"Gabapentin". Plumb's Veterinary Drugs. Retrieved 2 April 2021.

psychiatria-danubina.com (Global: low place; English: low place)

Bonnet U, Richter EL, Isbruch K, Scherbaum N (June 2018). "On the addictive power of gabapentinoids: a mini-review" (PDF). Psychiatria Danubina. 30 (2): 142–149. doi:10.24869/psyd.2018.142. PMID 29930223. S2CID 49344251.

publishing.service.gov.uk (Global: 1,837^th place; English: 948^th place)

assets.publishing.service.gov.uk

"Re: Pregabalin and Gabapentin advice" (PDF). GOV.UK. 14 January 2016.

reuters.com (Global: 38^th place; English: 30^th place)

Stempel J (2 June 2014). "Pfizer to pay $325 million in Neurontin settlement". Reuters. Retrieved 11 June 2018.
Berkrot B (25 March 2010). "US jury's Neurontin ruling to cost Pfizer $141 mln". Reuters. Archived from the original on 19 October 2015.
Hurley L (9 December 2013). "US high court leaves intact $142 million verdict against Pfizer". Reuters.

rug.nl (Global: 2,629^th place; English: 1,971^st place)

pure.rug.nl

Chan AY, Yuen AS, Tsai DH, Lau WC, Jani YH, Hsia Y, et al. (August 2023). "Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study" (PDF). Nature Communications. 14 (1) 5005. Bibcode:2023NatCo..14.5005C. doi:10.1038/s41467-023-40637-8. PMC 10435503. PMID 37591833.

sciencedirect.com (Global: 137^th place; English: 146^th place)

Prevo AJ, Slootman HJ, Harlaar J, Vogelaar TW (1985). "A new antispastic agent: gabapentin: its effect on EMG analysis during voluntary movement in hemiplegia". Clinical Neurophysiology. 62 (3): S221. doi:10.1016/0013-4694(85)90838-7.

scotusblog.com (Global: 6,074^th place; English: 2,913^th place)

"Pfizer Inc. v. Kaiser Foundation Health Plan, Inc.: Petition for certiorari denied on December 9, 2013". SCOTUSBlog.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Goa KL, Sorkin EM (September 1993). "Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy". Drugs. 46 (3): 409–427. doi:10.2165/00003495-199346030-00007. PMID 7693432. S2CID 265753780.
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. (September 2010). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". European Journal of Neurology. 17 (9): 1113–1e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID 20402746. S2CID 14236933.
Taylor CP, Harris EW (July 2020). "Analgesia with Gabapentin and Pregabalin May Involve N-Methyl-d-Aspartate Receptors, Neurexins, and Thrombospondins". The Journal of Pharmacology and Experimental Therapeutics. 374 (1): 161–174. doi:10.1124/jpet.120.266056. PMID 32321743. S2CID 216082872.
Henney JE (August 2006). "Safeguarding patient welfare: who's in charge?". Annals of Internal Medicine. 145 (4): 305–307. doi:10.7326/0003-4819-145-4-200608150-00013. PMID 16908923. S2CID 39262014.
Goodman CW, Brett AS (May 2019). "A Clinical Overview of Off-label Use of Gabapentinoid Drugs". JAMA Internal Medicine. 179 (5): 695–701. doi:10.1001/jamainternmed.2019.0086. PMID 30907944. S2CID 85497732.
"Review finds little evidence to support gabapentinoid use in bipolar disorder or insomnia". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 17 October 2022. doi:10.3310/nihrevidence_54173. S2CID 252983016.
Johannessen SI, Ben-Menachem E (2006). "Management of focal-onset seizures: an update on drug treatment". Drugs. 66 (13): 1701–1725. doi:10.2165/00003495-200666130-00004. PMID 16978035. S2CID 46952737.
Rheims S, Ryvlin P (July 2014). "Pharmacotherapy for tonic-clonic seizures". Expert Opinion on Pharmacotherapy. 15 (10): 1417–1426. doi:10.1517/14656566.2014.915029. PMID 24798217. S2CID 6943460.
Mula M, Pini S, Cassano GB (June 2007). "The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence". Journal of Clinical Psychopharmacology. 27 (3): 263–272. doi:10.1097/jcp.0b013e318059361a. PMID 17502773. S2CID 38188832.
Greenblatt HK, Greenblatt DJ (March 2018). "Gabapentin and Pregabalin for the Treatment of Anxiety Disorders". Clinical Pharmacology in Drug Development. 7 (3): 228–232. doi:10.1002/cpdd.446. PMID 29579375. S2CID 4321472.
Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS (2010). "Treatment effects of gabapentin for primary insomnia". Clinical Neuropharmacology. 33 (2): 84–90. doi:10.1097/WNF.0b013e3181cda242. PMID 20124884. S2CID 4046961.
Ahmed S, Stanciu CN, Kotapati PV, Ahmed R, Bhivandkar S, Khan AM, et al. (August 2019). "Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review". The Primary Care Companion for CNS Disorders. 21 (4). doi:10.4088/PCC.19r02465. PMID 31461226. S2CID 201662179.
McLean RJ, Gottlob I (August 2009). "The pharmacological treatment of nystagmus: a review". Expert Opinion on Pharmacotherapy. 10 (11): 1805–1816. doi:10.1517/14656560902978446. PMID 19601699. S2CID 21477128.
Thurtell MJ, Leigh RJ (February 2012). "Treatment of nystagmus". Current Treatment Options in Neurology. 14 (1): 60–72. doi:10.1007/s11940-011-0154-5. PMID 22072056. S2CID 40370476.
Mehta AR, Kennard C (June 2012). "The pharmacological treatment of acquired nystagmus". Practical Neurology. 12 (3): 147–153. doi:10.1136/practneurol-2011-000181. PMID 22661344. S2CID 1950738.
Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J (June 2020). "Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis". American Journal of Obstetrics and Gynecology. 222 (6): 564–579.e12. doi:10.1016/j.ajog.2019.12.011. PMID 31870736. S2CID 209462426.
Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, et al. (October 2016). "Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper". Multiple Sclerosis. 22 (11): 1386–1396. doi:10.1177/1352458516643600. PMID 27207462. S2CID 25028259.
Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. (July 2018). "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)^§". Movement Disorders. 33 (7): 1077–1091. doi:10.1002/mds.27260. PMID 29756335. S2CID 21669996.
Anand S (March 2013). "Gabapentin for pruritus in palliative care". The American Journal of Hospice & Palliative Care. 30 (2): 192–196. doi:10.1177/1049909112445464. PMID 22556282. S2CID 39737885.
Sadeghi R, Ondo WG (December 2010). "Pharmacological management of essential tremor". Drugs. 70 (17): 2215–2228. doi:10.2165/11538180-000000000-00000. PMID 21080739. S2CID 10662268.
Yang Y, Wang X (January 2016). "Sexual dysfunction related to antiepileptic drugs in patients with epilepsy". Expert Opinion on Drug Safety. 15 (1): 31–42. doi:10.1517/14740338.2016.1112376. PMID 26559937. S2CID 39571068.
Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY (November 2017). "Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review". Journal of the Neurological Sciences. 382: 36–39. doi:10.1016/j.jns.2017.09.019. PMID 29111014. S2CID 32010921.
Desai A, Kherallah Y, Szabo C, Marawar R (March 2019). "Gabapentin or pregabalin induced myoclonus: A case series and literature review". Journal of Clinical Neuroscience. 61: 225–234. doi:10.1016/j.jocn.2018.09.019. PMID 30381161. S2CID 53165515.
Leith WM, Lambert WE, Boehnlein JK, Freeman MD (January 2019). "The association between gabapentin and suicidality in bipolar patients". International Clinical Psychopharmacology. 34 (1): 27–32. doi:10.1097/YIC.0000000000000242. PMID 30383553. S2CID 54130760.
Rahman AA, Dell'Aniello S, Moodie EE, Durand M, Coulombe J, Boivin JF, et al. (January 2024). "Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study". Annals of Internal Medicine. 177 (Online ahead of print): 144–154. doi:10.7326/M23-0849. PMID 38224592. S2CID 266985259.
Mersfelder TL, Nichols WH (March 2016). "Gabapentin: Abuse, Dependence, and Withdrawal". The Annals of Pharmacotherapy. 50 (3): 229–233. doi:10.1177/1060028015620800. PMID 26721643. S2CID 21108959.
Bonnet U, Scherbaum N (December 2017). "How addictive are gabapentin and pregabalin? A systematic review". European Neuropsychopharmacology. 27 (12): 1185–1215. doi:10.1016/j.euroneuro.2017.08.430. PMID 28988943. S2CID 10345555.
Bonnet U, Richter EL, Isbruch K, Scherbaum N (June 2018). "On the addictive power of gabapentinoids: a mini-review" (PDF). Psychiatria Danubina. 30 (2): 142–149. doi:10.24869/psyd.2018.142. PMID 29930223. S2CID 49344251.
Calandre EP, Rico-Villademoros F, Slim M (November 2016). "Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Review of Neurotherapeutics. 16 (11): 1263–1277. doi:10.1080/14737175.2016.1202764. PMID 27345098. S2CID 33200190.
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (October 2010). "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin". Clinical Pharmacokinetics. 49 (10): 661–669. doi:10.2165/11536200-000000000-00000. PMID 20818832. S2CID 16398062.
Müller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chemistry & Biodiversity. 6 (11): 2071–2083. doi:10.1002/cbdv.200900114. PMID 19937841. S2CID 32513471.
Ma J, Björnsson ES, Chalasani N (February 2024). "The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review". Am J Med. 137 (2): 99–106. doi:10.1016/j.amjmed.2023.10.022. PMID 37918778. S2CID 264888110.
Mayor S (October 2018). "Pregabalin and gabapentin become controlled drugs to cut deaths from misuse". BMJ. 363 k4364. doi:10.1136/bmj.k4364. PMID 30327316. S2CID 53520780.
Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (October 2011). "Modeling sleep data for a new drug in development using markov mixed-effects models". Pharmaceutical Research. 28 (10): 2610–2627. doi:10.1007/s11095-011-0490-x. PMID 21681607. S2CID 22241527.
Shebak S, Varipapa R, Snyder A, Whitham MD, Milam TR (2014). "Gabapentin abuse and overdose: a case report" (PDF). J Subst Abus Alcohol. 2: 1018. S2CID 8959463. Archived from the original (PDF) on 2 March 2019.
Martinez GM, Olabisi J, Ruekert L, Hasan S (July 2019). "A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report". Journal of Psychiatric Practice. 25 (4): 308–312. doi:10.1097/PRA.0000000000000403. PMID 31291212. S2CID 195878855.
Evoy KE, Morrison MD, Saklad SR (March 2017). "Abuse and Misuse of Pregabalin and Gabapentin". Drugs. 77 (4): 403–426. doi:10.1007/s40265-017-0700-x. PMID 28144823. S2CID 24396685.
Reynolds K, Kaufman R, Korenoski A, Fennimore L, Shulman J, Lynch M (July 2020). "Trends in gabapentin and baclofen exposures reported to U.S. poison centers". Clinical Toxicology. 58 (7): 763–772. doi:10.1080/15563650.2019.1687902. PMID 31786961. S2CID 208537638.
Faryar KA, Webb AN, Bhandari B, Price TG, Bosse GM (June 2019). "Trending gabapentin exposures in Kentucky after legislation requiring the use of the state prescription drug monitoring program for all opioid prescriptions". Clinical Toxicology. 57 (6): 398–403. doi:10.1080/15563650.2018.1538518. PMID 30676102. S2CID 59226292.
van Haaften KA, Forsythe LR, Stelow EA, Bain MJ (November 2017). "Effects of a single preappointment dose of gabapentin on signs of stress in cats during transportation and veterinary examination". Journal of the American Veterinary Medical Association. 251 (10): 1175–1181. doi:10.2460/javma.251.10.1175. PMID 29099247. S2CID 7780988.

pdfs.semanticscholar.org

Shebak S, Varipapa R, Snyder A, Whitham MD, Milam TR (2014). "Gabapentin abuse and overdose: a case report" (PDF). J Subst Abus Alcohol. 2: 1018. S2CID 8959463. Archived from the original (PDF) on 2 March 2019.

sfgate.com (Global: 248^th place; English: 142^nd place)

Tansey B (14 May 2004). "Huge penalty in drug fraud, Pfizer settles felony case in Neurontin off-label promotion". San Francisco Chronicle. p. C-1. Archived from the original on 23 June 2006.

springer.com (Global: 182^nd place; English: 172^nd place)

adisinsight.springer.com

"Drug Profile: Gabapentin". Adis Insight.
"Gabapentin controlled release – Depomed". Adis Insight.

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

thestreet.com (Global: 5,850^th place; English: 3,428^th place)

Feuerstein A (13 November 2007). "Hythiam, Shire, Genentech; Talk is proving cheap at Hythiam". Biotech Notebook. TheStreet.

tn.gov (Global: 4,493^rd place; English: 2,108^th place)

"Gabapentin will be a Schedule V controlled substance in Tennessee effective July 1, 2018" (PDF). tn.gov. Archived from the original (PDF) on 27 October 2019. Retrieved 30 May 2020.

ucl.ac.uk (Global: 1,187^th place; English: 756^th place)

discovery.ucl.ac.uk

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, et al. (October 2016). "Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper". Multiple Sclerosis. 22 (11): 1386–1396. doi:10.1177/1352458516643600. PMID 27207462. S2CID 25028259.

usdoj.gov (Global: 4,271^st place; English: 2,616^th place)

deadiversion.usdoj.gov

"Gabapentin (Neurontin)" (PDF). Drug Enforcement Administration. January 2023.

utah.gov (Global: 2,710^th place; English: 1,330^th place)

le.utah.gov

"Controlled Substances Amendments". Utah State Legislature. Retrieved 12 April 2024.

viatris.com (Global: low place; English: low place)

"Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

virginia.gov (Global: 1,338^th place; English: 592^nd place)

dhp.virginia.gov

"Scheduling of Gabapentin" (PDF). Virginia Department of Health Professions. Retrieved 28 June 2023.

washingtonmonthly.com (Global: 6,261^st place; English: 3,625^th place)

Humphreys K (24 January 2012). "The Rise and Fall of a "Miracle Cure" for Drug Addiction". Washington Monthly.

web.archive.org (Global: 1^st place; English: 1^st place)

"International listings for Gabapentin". Drugs.com. Archived from the original on 16 February 2016. Retrieved 9 February 2016.
Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
"Neurontin, Gralise (gabapentin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 16 December 2014. Retrieved 6 April 2014.
Pitkänen A, Schwartzkroin PA, Moshé SL (2005). Models of Seizures and Epilepsy. Burlington: Elsevier. p. 539. ISBN 978-0-08-045702-4. Archived from the original on 8 September 2017.
"The Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
Sobel SV (5 November 2012). Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission. W. W. Norton. p. 124. ISBN 978-0-393-70857-8. Archived from the original on 6 January 2016.
Hamilton TW, Strickland LH, Pandit HG (August 2016). "A Meta-Analysis on the Use of Gabapentinoids for the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty". The Journal of Bone and Joint Surgery. American Volume. 98 (16): 1340–1350. doi:10.2106/jbjs.15.01202. PMID 27535436. Archived from the original on 29 September 2020. Retrieved 22 August 2020.
"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)". U.S. Food and Drug Administration (FDA). 19 December 2019. Archived from the original on 22 December 2019. Retrieved 21 December 2019. This article incorporates text from this source, which is in the public domain.
Mack A (2003). "Examination of the evidence for off-label use of gabapentin" (PDF). Journal of Managed Care Pharmacy. 9 (6): 559–568. doi:10.18553/jmcp.2003.9.6.559. PMC 10437292. PMID 14664664. Archived from the original (PDF) on 17 September 2010. Retrieved 15 August 2006.
Orrange S (31 May 2013). "Yabba Dabba Gabapentin: Are Gralise and Horizant Worth the Cost?". GoodRx, Inc. Archived from the original on 23 June 2018. Retrieved 22 June 2018.
"Pregabalin and gabapentin will become controlled drugs in April". NursingNotes. 17 October 2018. Archived from the original on 16 June 2019. Retrieved 16 June 2019.
"Important Notice: Gabapentin Becomes a Schedule 5 Controlled Substance in Kentucky" (PDF). Kentucky State Board of Pharmacy. March 2017. Archived from the original (PDF) on 4 June 2018. Retrieved 18 June 2018.
"Gabapentin will be a Schedule V controlled substance in Tennessee effective July 1, 2018" (PDF). tn.gov. Archived from the original (PDF) on 27 October 2019. Retrieved 30 May 2020.
Tansey B (14 May 2004). "Huge penalty in drug fraud, Pfizer settles felony case in Neurontin off-label promotion". San Francisco Chronicle. p. C-1. Archived from the original on 23 June 2006.
Berkrot B (25 March 2010). "US jury's Neurontin ruling to cost Pfizer $141 mln". Reuters. Archived from the original on 19 October 2015.
"Pfizer faces $142M in damages for drug fraud". Bloomberg Businessweek. 25 March 2010. Archived from the original on 19 October 2015. Retrieved 13 January 2012.
Van Voris B, Lawrence J (26 March 2010). "Pfizer Told to Pay $142.1 Million for Neurontin Marketing Fraud". Bloomberg News. Archived from the original on 13 May 2013. Retrieved 13 January 2012.
"Prometa Founder's Spotty Background Explored". 3 November 2006. Archived from the original on 23 September 2015.
"Santa Monica man used anti-insider-trading measure to commit fraud: DOJ". 1 March 2023. Archived from the original on 28 March 2023. Retrieved 30 March 2023.
Ramshaw E (20 January 2008). "Texas' Prometa program for treating meth addicts draws skeptics". Dallas Morning News. Archived from the original on 27 October 2010.
Shebak S, Varipapa R, Snyder A, Whitham MD, Milam TR (2014). "Gabapentin abuse and overdose: a case report" (PDF). J Subst Abus Alcohol. 2: 1018. S2CID 8959463. Archived from the original (PDF) on 2 March 2019.
Coile C (31 October 2022). "Gabapentin for Dogs: Uses and Side Effects". American Kennel Club. Archived from the original on 6 December 2022. Retrieved 12 May 2023.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Wessely P, Baumgartner C, Klingler D, Kreczi J, Meyerson N, Sailer L, et al. (1987). "Preliminary Results Of A Double Blind Study With The New Migraine Prophylactic Drug Gabapentin". Cephalalgia. 7 (6_suppl): 477–478. doi:10.1177/03331024870070S6214. ISSN 0333-1024.

wsj.com (Global: 94^th place; English: 66^th place)

Dave Michaels (21 June 2024). "Jury Convicts Milken Protégé Terren Peizer of Insider Trading," The Wall Street Journal.
Alpert B (7 November 2005). "Curb Your Cravings For This Stock". The Wall Street Journal.
McKay B, Ramachandran S (25 December 2025). "The Hidden Risks of America's Most Popular Prescription Painkiller". The Wall Street Journal. Retrieved 31 December 2025.

wvlegislature.gov (Global: low place; English: 7,613^th place)

"WV Code 212". West Virginia Legislature. Retrieved 30 May 2020.

Gabapentin (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

akc.org (Global: 2,789th place; English: 2,304th place)

alabamapublichealth.gov (Global: low place; English: low place)

amcp.org (Global: low place; English: low place)

bloomberg.com (Global: 118th place; English: 85th place)

bmj.com (Global: 1,341st place; English: 1,425th place)

jnnp.bmj.com

books.google.com (Global: 3rd place; English: 3rd place)

businessweek.com (Global: 945th place; English: 628th place)

businesswire.com (Global: 828th place; English: 485th place)

cbsnews.com (Global: 136th place; English: 93rd place)

clincalc.com (Global: 5,833rd place; English: 4,432nd place)

dallasnews.com (Global: 903rd place; English: 457th place)

doi.org (Global: 2nd place; English: 2nd place)

drugfree.org (Global: low place; English: low place)

drugs.com (Global: 529th place; English: 550th place)

fass.se (Global: low place; English: low place)

fda.gov (Global: 470th place; English: 329th place)

goodrx.com (Global: low place; English: low place)

gov.uk (Global: 401st place; English: 228th place)

hdl.handle.net (Global: 66th place; English: 34th place)

healthcarelawinsights.com (Global: low place; English: low place)

helmholtz-muenchen.de (Global: low place; English: low place)

push-zb.helmholtz-muenchen.de

in.gov.br (Global: 3,835th place; English: 6,615th place)

justice.gov (Global: 884th place; English: 477th place)

ktla.com (Global: 5,255th place; English: 2,760th place)

ky.gov (Global: 2,697th place; English: 1,238th place)

pharmacy.ky.gov

mayoclinic.org (Global: 2,191st place; English: 1,798th place)

medicalnewstoday.com (Global: 3,865th place; English: 3,829th place)

medscape.com (Global: 1,078th place; English: 916th place)

reference.medscape.com

nbcnews.com (Global: 156th place; English: 101st place)

nhs.uk (Global: 2,637th place; English: 2,254th place)

nice.org.uk (Global: 4,081st place; English: 3,905th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

nihr.ac.uk (Global: low place; English: 7,409th place)

evidence.nihr.ac.uk

nursingnotes.co.uk (Global: low place; English: low place)

nytimes.com (Global: 7th place; English: 7th place)

osf.io (Global: 8,809th place; English: 5,705th place)

ox.ac.uk (Global: 541st place; English: 356th place)

ora.ox.ac.uk

patents.google.com (Global: 1,154th place; English: 606th place)

pfizer.com (Global: low place; English: low place)

plumbsveterinarydrugs.com (Global: low place; English: low place)

psychiatria-danubina.com (Global: low place; English: low place)

publishing.service.gov.uk (Global: 1,837th place; English: 948th place)

assets.publishing.service.gov.uk

reuters.com (Global: 38th place; English: 30th place)

rug.nl (Global: 2,629th place; English: 1,971st place)

pure.rug.nl

sciencedirect.com (Global: 137th place; English: 146th place)

scotusblog.com (Global: 6,074th place; English: 2,913th place)

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

pdfs.semanticscholar.org

sfgate.com (Global: 248th place; English: 142nd place)

springer.com (Global: 182nd place; English: 172nd place)

adisinsight.springer.com

tga.gov.au (Global: 4,353rd place; English: 2,806th place)

thestreet.com (Global: 5,850th place; English: 3,428th place)

tn.gov (Global: 4,493rd place; English: 2,108th place)

ucl.ac.uk (Global: 1,187th place; English: 756th place)

discovery.ucl.ac.uk

usdoj.gov (Global: 4,271st place; English: 2,616th place)

deadiversion.usdoj.gov

utah.gov (Global: 2,710th place; English: 1,330th place)

le.utah.gov

viatris.com (Global: low place; English: low place)

virginia.gov (Global: 1,338th place; English: 592nd place)

dhp.virginia.gov

washingtonmonthly.com (Global: 6,261st place; English: 3,625th place)

web.archive.org (Global: 1st place; English: 1st place)

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

akc.org (Global: 2,789^th place; English: 2,304^th place)

bloomberg.com (Global: 118^th place; English: 85^th place)

bmj.com (Global: 1,341^st place; English: 1,425^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

businessweek.com (Global: 945^th place; English: 628^th place)

businesswire.com (Global: 828^th place; English: 485^th place)

cbsnews.com (Global: 136^th place; English: 93^rd place)

clincalc.com (Global: 5,833^rd place; English: 4,432^nd place)

dallasnews.com (Global: 903^rd place; English: 457^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 529^th place; English: 550^th place)

fda.gov (Global: 470^th place; English: 329^th place)

gov.uk (Global: 401^st place; English: 228^th place)

hdl.handle.net (Global: 66^th place; English: 34^th place)

in.gov.br (Global: 3,835^th place; English: 6,615^th place)

justice.gov (Global: 884^th place; English: 477^th place)

ktla.com (Global: 5,255^th place; English: 2,760^th place)

ky.gov (Global: 2,697^th place; English: 1,238^th place)

mayoclinic.org (Global: 2,191^st place; English: 1,798^th place)

medicalnewstoday.com (Global: 3,865^th place; English: 3,829^th place)

medscape.com (Global: 1,078^th place; English: 916^th place)

nbcnews.com (Global: 156^th place; English: 101^st place)

nhs.uk (Global: 2,637^th place; English: 2,254^th place)

nice.org.uk (Global: 4,081^st place; English: 3,905^th place)

nih.gov (Global: 5^th place; English: 5^th place)

nihr.ac.uk (Global: low place; English: 7,409^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

osf.io (Global: 8,809^th place; English: 5,705^th place)

ox.ac.uk (Global: 541^st place; English: 356^th place)

patents.google.com (Global: 1,154^th place; English: 606^th place)

publishing.service.gov.uk (Global: 1,837^th place; English: 948^th place)

reuters.com (Global: 38^th place; English: 30^th place)

rug.nl (Global: 2,629^th place; English: 1,971^st place)

sciencedirect.com (Global: 137^th place; English: 146^th place)

scotusblog.com (Global: 6,074^th place; English: 2,913^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

sfgate.com (Global: 248^th place; English: 142^nd place)

springer.com (Global: 182^nd place; English: 172^nd place)

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

thestreet.com (Global: 5,850^th place; English: 3,428^th place)

tn.gov (Global: 4,493^rd place; English: 2,108^th place)

ucl.ac.uk (Global: 1,187^th place; English: 756^th place)

usdoj.gov (Global: 4,271^st place; English: 2,616^th place)

utah.gov (Global: 2,710^th place; English: 1,330^th place)

virginia.gov (Global: 1,338^th place; English: 592^nd place)

washingtonmonthly.com (Global: 6,261^st place; English: 3,625^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 4^th place; English: 4^th place)

wsj.com (Global: 94^th place; English: 66^th place)

wvlegislature.gov (Global: low place; English: 7,613^th place)